PMGC Holdings Inc. (ELAB): Gross Profit

Annual figures by period end, from SEC filings.

$185.3K
Year ended 2025-12-31
$1.32M
Trailing 12 months to 2026-09-30
-25.5%
3-year compound annual growth
$1.13M2022-12-31: $447.3K2023-12-31: $1.13M2025-12-31: $185.3K$185.3K
2022-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$185.3Kn/a2026-03-30, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31$1.13M+153.6%2024-03-29, From 2023-01-01
2022-12-31$447.3Kn/a2024-03-29, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
PMGC Holdings Inc. (ELAB)2025-12-31$185.3Kn/a
Silence Therapeutics plc (SLN)2025-12-31$344.0K-98.9%
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$478.0K+288.6%
Polomar Health Services, Inc. (PMHS)2025-12-31$460.1Kn/m
Quantum Cyber N.V. (QUCY)2025-12-31$389.8K-32.2%
Lexaria Bioscience Corp. (LEXX)2025-08-31$703.2K+53.1%
Scienture Holdings, Inc. (SCNX)2025-12-31$331.5Kn/m
Onconetix, Inc. (ONCO)2025-12-31$632.9K-40.0%
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$223.8K+0.4%

Compare ELAB, SLN, BTAIQ, PMHS side by side · Screen every company in Pharmaceutical Preparations ↗